| 초록 |
Antibody therapeutics are second-generation biotherapeutics, accounting for 48% of the total biotherapeutical markets. An important step of antibody therapeutics production process is the separation and purification of the antibodies, in which various chromatography is used. Especially, affinity chromatography using Protein A ligand is essential process. However, most antibody purification resins are dependent on foreign companies, so it necessary to localize through domestic technology development. These affinity chromatography resins are consisted of 1) antibody binding ligand, 2) embodiment (or matrix) for immobilization of the ligand, and 3) coupling technique. We tried to develop a technology for manufacturing affinity chromatography resins using our own coupling technology and antibody binding ligand. Also the ligand protein was engineered to improve alkali-resistant from Protein A. |
